Dec 05, 2019 - Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.
Dec 05, 2019 - Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Dec 04, 2019 - Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Dec 03, 2019 - Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Nov 29, 2019 - Here's why the FDA recently approved five new drugs way ahead of schedule.
Nov 28, 2019 - The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Nov 25, 2019 - The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.